Form 4: Pulse Biosciences Director Acquires Shares in Open Market Transaction

Robert W. Duggan, a director at Pulse Biosciences, purchased 55,256 shares of common stock at a price of $17.18 per share on December 13, 2024.

Summary

• Robert W. Duggan, a director of Pulse Biosciences, acquired 55,256 shares of common stock on December 13, 2024.
• The shares were purchased at a price of $17.18 per share.
• Following the transaction, Mr. Duggan directly owns 42,328,717 shares of Pulse Biosciences common stock.
• He also indirectly owns 561,089 shares through Genius 24C Inc. and 400,877 shares through Blazon Corporation.
• Mr. Duggan is the sole shareholder of both Genius 24C Inc. and Blazon Corporation.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment due to a director increasing their stake in the company, which is generally seen as a sign of confidence. However, it is a routine filing and not a major event.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.
• The purchase increases the director's stake in the company, aligning his interests with those of other shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade company stock. It provides transparency into the trading activities of company directors and officers.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for directors who are increasing their stake in the company.

Stakeholder Impact

• The share purchase may positively influence investor confidence in Pulse Biosciences.
• The increased stake of a director aligns their interests with those of other shareholders.

Key Dates

Keywords

Pulse Biosciences, insider trading, share purchase, Robert W. Duggan, director, stock acquisition, PLSE